ALK and neoplasm: Since ALK rearrangement was involved in various tumor types, Mariño-Enríquez et al. posited that either direct ALK inhibitors (e.g., crizotinib) or indirect ALK inhibitors (e.g., HSP90 inhibitors) could be a potential novel treatment for RMC [65].